Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology

Condition(s) studied

Study summary

Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage.

It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.

Eligibility

Primary outcome measure(s)

• Detectable serum neural autoantibodies — at baseline
  such as NMDAR、AMPAR1、AMPAR2、LGI1、lg LON5、DPPX、GAD65、mGluR5、MOG
• Neuronal surface antibodies-mediated autoimmune- encephalitis — at baseline
  diagnosed according to the 2016 diagnostic criteria

Trial sites (1)

More Shen Chun-Hong trials in China

Other trials for the same condition